Birute B.
- Country
- Lithuania
- Department
- Center of Medical Oncology
Research Overview
- Phase 3 Study Comparing Rinatabart Sesutecan Versus Investigator's Choice in Patients With Recurrent or Progressive Endometrial Cancer Following Platinum-Based and PD(L)-1 Therapy
- Evaluation of LSTA1 Combined with Temozolomide Versus Temozolomide Alone in Newly Diagnosed Glioblastoma Multiforme: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Olaparib, Durvalumab, and UV1 as Maintenance Therapy in BRCA Wild-Type Recurrent Ovarian Cancer: A Randomized Clinical Trial
Data & Insights
Has run more than one trial at 91 of 231 partner sites.
Specializations
Gynecologic Oncology
The investigator specializes in treating advanced gynecological malignancies, with particular emphasis on ovarian cancer and endometrial cancer management.
- Advanced and Recurrent Endometrial Cancer
- Platinum-Resistant Ovarian Cancer
- Fallopian Tube and Peritoneal Cancers
Active involvement in therapeutic approaches for patients with specific genetic profiles including TP53WT and BRCAwt mutations.
Therapeutic Approaches
Expertise in developing maintenance therapy strategies for gynecologic cancers, incorporating both targeted and immunotherapy treatments.
- Combination Immunotherapy
- Targeted Molecular Therapies
- Platinum-Based Treatment Protocols
Focus on novel therapeutic combinations including immune checkpoint inhibitors and molecular targeted agents.
Treatment Innovation
Specializes in evaluating novel therapeutic combinations for gynecologic cancers, particularly in the maintenance setting.
- Advanced Treatment Protocols
- Maintenance Therapy Strategies
- Combination Treatment Approaches
Expertise in assessing survival outcomes and developing treatment strategies for resistant disease states.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.